← Back to patent-cliff list
Istaroxime
Tier C — Watch / tradeIstaroxime
Sigma-Tau Spa
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Na+/K+ ATPase, ATP2A2
Indications (approved)：Cardiogenic shock, Heart failure, Acute decompensated heart failure
Regional status
US
Phase II
2020-09-28
EU
Phase II
2013-09-24
China
No progress
2015-12-01
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Istaroxime?
Approved indications include: Cardiogenic shock, Heart failure, Acute decompensated heart failure.
When does the Istaroxime patent expire?
No public expiry year is available for Istaroxime yet; this page updates once verified.
How do I get a quote for Istaroxime intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-28